FDA Approval of First Fecal Microbiota Product Ensures Safety in Standardization
December 7th 2022Ferring Chief Scientific Officer Dr. Elizabeth Garner explains the FDA approval of recurrent C diff treatment RBX2660 provides more than a treatment option, it’s a promise of safety and standardization.
Watch
Reevaluating Susceptibility Breakpoints
October 24th 2022After the Clinical and Laboratory Standards Institute (CLSI) revised their clinical breakpoints for susceptibility test results, a laboratory at a major medical center in a large midwest city evaluated enterobacterales as it relates to bloodstream infections (BSI) and piperacillin/tazobactam.
Watch